Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma
Clinical trial NCT07715097 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07715097
- Sponsor
- Beijing Tricision Biotherapeutics Inc
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-30
- Primary completion
- 2028-09-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.